Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 951 | 108 | 834 |
| Samples | 329 | 58 | 268 |
| Peptides | 233 | 37 | 197 |
Function
MAGEB1 · MAGE family member B1
This gene is a member of the MAGEB gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 68% sequence identity to each other. The promoters and first exons of the MAGEB genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. This gene is localized in the DSS (dosage-sensitive sex reversal) critical region, and expressed in testis and in a significant fraction of tumors of various histological types. This gene and other MAGEB members are clustered on chromosome Xp22-p21. Multiple alternatively spliced transcript variants encoding the same protein have been found for this gene, however, the full length nature of some variants has not been defined. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 233 amino-acid changes on canonical ENST00000397548 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MAGEB1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MAGEB1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 1/42 2% | 20/612 3% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 17/810 2% |
| Melanoma | 6/210 3% | 36/1899 2% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 22/1390 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Other Solid Cancers | 4/94 4% | 19/1515 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Gastric Carcinoma | 4/74 5% | 17/1809 1% |
| Colorectal Carcinoma | 5/143 4% | 33/3239 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Neuroendocrine Tumour | 6/154 4% | 1/577 0% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Pancreatic Carcinoma | 3/89 3% | 10/1611 1% |
| Bladder Carcinoma | 1/58 2% | 6/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Breast Carcinoma | 5/144 3% | 16/3264 0% |
| Glioma | 0/52 0% | 11/2127 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Ovarian Carcinoma | 1/109 1% | 3/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
| Neuroblastoma | 0/87 0% | 4/1331 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 5/2534 0% |
| Other Blood Cancers | 2/61 3% | 3/2725 0% |
Mutation Distribution
Where MAGEB1 is mutated · all tissues, split by cell line vs tissue
How many mutations in MAGEB1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 2 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 951 mutations in MAGEB1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|